Phio Pharmaceuticals Corp. PHIO
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$8.7M | — | -$8.0M | $20.1M |
| 2024 | — | -$7.2M | — | -$7.1M | $4.7M |
| 2023 | — | -$10.8M | — | -$10.8M | $7.7M |
| 2022 | — | -$11.5M | — | -$12.2M | $10.8M |
| 2021 | — | -$13.3M | — | -$11.9M | $21.9M |
| 2020 | $0 | -$8.8M | — | -$8.8M | $13.0M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Source: SEC EDGAR filings · CIK 0001533040 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.